Sunday, November 1, 2026

AI Credit Models Cut Loan Losses 30-70% Across US Lenders as Global Banks Eye Adoption

Pagaya's AI platform reduced personal loan losses 30-40% and auto loan losses 50-70% versus 2022 by analyzing real-time data across 30+ US lenders. The system detected market risk patterns before traditional metrics showed borrower stress, cutting Q4 2024 volume by $100-150M while maintaining margins. The performance gap highlights AI's advantage over quarterly model updates used by most global banks.

ViaNews Editorial Team

February 21, 2026

AI Credit Models Cut Loan Losses 30-70% Across US Lenders as Global Banks Eye Adoption
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Pagaya's AI credit platform cut personal loan losses 30-40% and auto loan losses 50-70% compared to 2022 vintages by processing early market signals across 30+ institutional lenders in the United States. The fintech's machine learning models detected elevated risk in specific borrower segments during late 2024 despite finding no direct consumer deterioration—reducing Q4 volume by $100-150 million while preserving profit margins.

The approach contrasts with traditional banking models worldwide. Most lenders analyze their own portfolios in isolation and update credit scoring quarterly or annually. Pagaya's AI ingests real-time performance data across three asset classes simultaneously, spotting cross-market correlations human analysts miss. When models flagged risk in H2 2024, the system tightened underwriting parameters within days rather than quarters.

Scale drives the speed advantage. Monitoring billions in loans across dozens of partners creates data volume no single bank matches. Machine learning models update risk weights continuously as payment data arrives, adjusting approved amounts and interest rates for incoming applications without manual intervention. This continuous learning approach is gaining attention from financial institutions across Europe and Asia exploring AI adoption.

Cumulative net loss rates for H2 2024 through H1 2025 originations ran 30-40% below H1 2024 vintages in personal loans. Auto loans showed sharper improvement at 50-70% better than 2022. These gains emerged despite the AI finding no concrete evidence of borrower quality decline in its datasets.

The paradox illustrates AI's predictive edge over conventional credit analysis used by banks globally. Where human officers wait for delinquency spikes to confirm downturns, machine learning detects subtle shifts in payment timing, credit utilization changes, and cross-asset correlations. Pagaya's models recommended defensive positioning based on second-order indicators rather than direct consumer stress signals.

Dynamic pricing algorithms maintained profitability despite the $100-150M volume drop. The AI reallocated exposure from constrained categories to higher-margin opportunities faster than manual portfolio management allows. This performance gap between AI-native lenders and traditional institutions is widening as continuous learning systems improve daily while legacy models update quarterly, creating accuracy advantages that translate to loss rate differentials approaching 50% in some asset classes.


Sources:
1 Yahoo Finance, "Pagaya Technologies Ltd. (PGY) Advances While Market Declines: Some Information for Investors" (March 19, 2026)
2 News Report, "Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility" (March 18, 2026)
3 Nasdaq, "Japanese Market Tumbling 4.7%" (March 23, 2026)
4 Yahoo Finance, "AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push" (March 23, 2026)
5 Globe Newswire, "Olympians Inspire Expands School Assembly and Leadership Workshop Programming Featuring Elite Athlet" (March 23, 2026)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com